Millions worldwide could benefit after breakthrough trial in treatment for Alzheimer’s


Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s by Aussie biotech Actinogen

Aussie biotech firm Actinogen has announced that their most recent trial of Xanamem has demonstrated improved attention and working memory.

Sydney, 27 April 2022. Actinogen Medical has announced positive results for their lead drug Xanamem taking the Aussie biotech a big step closer to creating a novel treatment for a disease that impacts over 400,000 elderly Australians.

“These results are an important replication of previous trial findings also conducted in a cognitively normal population. The positive effects on attention and working memory seen in the XanaMIA trial are a significant step in the development of a new treatment for Alzheimer’s Disease with a novel mechanism of action,” said international cognition expert, Professor John Harrison.

In a release to the ASX Actinogen reported that the trial had met its objectives with the efficacy endpoint of the Xanamem trial defined as clinically significant on the treatment on cognitive ability and confirmed Xanamem’s ability to enhance attention and working memory whilst demonstrating a good safety profile.

“We are excited to see the positive clinical data for these lower Xanamem dose levels. Xanamem has the potential to be a novel daily oral therapy for Alzheimer’s Disease and other conditions that could be safely used alone or in combination with other therapies. Our future clinical trials will evaluate if Xanamem can make a significant improvement in the lives of patients and their families living with serious neurological conditions,” said Actinogen’s CEO Dr Steven Gourlay.

The Xanamem low dose-ranging trial was conducted in a population of 107 healthy, cognitively normal, older adults aged 50-80 years, with a mean age of 64 years and a gender ratio of one male to two females, with trial participants randomised to receive either 10 mg or 5 mg doses of Xanamem or matching placebo for a six-week treatment period.

It is the second trial conducted by Actinogen that has shown positive results for the potential treatment of Alzheimer’s by Actinogen’s lead drug Xanamem moving the Aussie biotech a big step closer to a groundbreaking treatment of a condition that impacts millions worldwide.

Actinogen will now review detailed results of the Xanamem trial with academic and industry experts as it finalises the design of its next Alzheimer’s disease program trial. Detailed results will be published at a future scientific congress and in a peer-reviewed journal.



/Public Release.